SCHEMBL13922232

SCHEMBL13922232

CC(C)C1CCC(c2ccc(Nc3ccc(-c4cc[nH]c(=O)c4)n4ccnc34)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 4/20 0.47
ROCK2 O75116 1/20 0.35
SYK P43405 1/20 0.32
ZAP70 P43403 1/20 0.31
TLR9 Q9NR96 1/20 0.31
TLR8 Q9NR97 1/20 0.31
TLR7 Q9NYK1 1/20 0.31
JAK2 O60674 5/20 0.31
BRD4 O60885 2/20 0.31
JAK3 P52333 4/20 0.31
PTK2 Q05397 3/20 0.31
WEE1 P30291 2/20 0.30
JAK1 P23458 1/20 0.30
BRD2 P25440 1/20 0.30
BRD3 Q15059 1/20 0.30
BRDT Q58F21 1/20 0.30
SCN8A Q9UQD0 1/20 0.30
SCN10A Q9Y5Y9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134512 0.89 MAPKAPK5 (0.48) MAPKAPK5ROCK2SYKZAP70TLR9
SCHEMBL10133578 0.88 MAPKAPK5 (0.49) MAPKAPK5ROCK2SYKZAP70JAK2
SCHEMBL10134523 0.88 MAPKAPK5 (0.49) MAPKAPK5ROCK2JAK2BRD4JAK3
SCHEMBL13922281 0.86 MAPKAPK5 (0.45) MAPKAPK5ROCK2SYKZAP70JAK2
SCHEMBL13922280 0.85 MAPKAPK5 (0.48) MAPKAPK5SYK
SCHEMBL12618871 0.84 MAPKAPK5 (0.49) MAPKAPK5ROCK2ZAP70TLR9TLR8
SCHEMBL13922211 0.84 MAPKAPK5 (0.36) MAPKAPK5ROCK2ZAP70TLR9TLR8
SCHEMBL1685281 0.83 MAPKAPK5 (0.45) MAPKAPK5ROCK2ZAP70TLR9TLR8
SCHEMBL13922272 0.83 MAPKAPK5 (0.43) MAPKAPK5ROCK2ZAP70JAK1SCN8A
SCHEMBL12619378 0.83 MAPKAPK5 (0.46) MAPKAPK5ROCK2ZAP70TLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885ROCK2 1106/4885SYK 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.